CAR T-cell therapy industry generated $1.7 billion in 2021, and is expected to reach $6.1 billion by 2031, witnessing a CAGR of 13.5% from 2022 to 2031. Increase in demand for ideal therapeutics for cancer treatment, rise in prevalence of cancer, supportive reimbursement policies in some countries related to CAR T-cell therapy medicine, and surge in awareness of CAR T-cell therapy medicines drive the growth of the global CAR T-cell therapy market. However, lack of skilled professionals for CAR T-cell therapy and high cost of therapy hinder the market growth. On the other hand, rise in approval of new medicine of CAR T-cell therapy and drugs present new opportunities in the coming years.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Autolus
- Bluebird Bio-Inc.
- Bristol-Myers Squibb
- Caribou Biosciences Inc.
- Cartesian Therapeutics
- Celgene Corporation
- Cellectis
- Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.)
- Intellia Therapeutics
- Juno Therapeutics
- Merck & Co. Inc.
- Miltenyi Biotech
- Novartis AG
- Pfizer Inc.
- Sorrento Therapeutics, Inc.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/17358
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
- The number of CAR T-cell therapies reduced considerably during the Covid-19 pandemic, due to shift of resources toward treatment of increasing Covid-infected patients. Governments of many countries released guidelines that postponed the non-elective surgeries.
- Discovery and development activities of CAR T-cell therapy medicine slowed down significantly. The decrease in number of clinical trials impacted the CAR T-cell therapy market size.
- Supply chain disruptions due to lockdown measures and ban on import-export activities created a supply-demand gap. This, in turn, impacted the overall market revenue.
- Post-pandemic, the development activities of CAR T-cell therapy medicine are expected to increase with rise in R&D activities, rapidly expanding clinical trial activities, and commercialization.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/17358
Based on indication, the lymphoma segment accounted for the highest market share in 2021, contributing to more than half of the global CAR T-cell therapy market, and is projected to maintain its leadership status during the forecast period. This is attributed to high number of approved CAR T-cell therapeutics for treatment of different forms of lymphoma. However, the acute lymphocytic leukemia segment is estimated to witness the highest CAGR of 14.5% from 2022 to 2031. This is due to increase in awareness of CAR T-cell therapeutics for treatment of acute lymphocytic leukemia and launch of novel drugs.
Based on end user, the hospitals segment contributed to the highest market share in 2021, holding nearly three-fifths of the global CAR T-cell therapy market, and is projected to maintain its lead position during the forecast period. This is attributed to well-equipped operation theatre and high purchasing power. However, the cancer treatment centers segment is estimated to register the highest CAGR of 14.1% from 2022 to 2031, owing to availability of a wide range of treatment choices and increase in a
Based on drug type, the axicabtagene ciloleucel segment held the largest market share in 2021, accounting for around two-fifths of the global CAR T-cell therapy market, and is expected to maintain its dominant share during the forecast period. This is due to increase in adoption of axicabtagene ciloleucel for treatment of relapsed or refractory large B-cell lymphoma and relapsed or refractory follicular lymphoma. However, the brexucabtagene autoleucel segment is projected to grow at the highest CAGR of 15.9% from 2022 to 2031, owing to rise in approval of CAR T-cell therapies in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com